JP2014516088A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516088A5
JP2014516088A5 JP2014514934A JP2014514934A JP2014516088A5 JP 2014516088 A5 JP2014516088 A5 JP 2014516088A5 JP 2014514934 A JP2014514934 A JP 2014514934A JP 2014514934 A JP2014514934 A JP 2014514934A JP 2014516088 A5 JP2014516088 A5 JP 2014516088A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
rvwf
vwf
subject
von willebrand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014514934A
Other languages
English (en)
Japanese (ja)
Other versions
JP6347468B2 (ja
JP2014516088A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/041957 external-priority patent/WO2012171031A1/en
Publication of JP2014516088A publication Critical patent/JP2014516088A/ja
Publication of JP2014516088A5 publication Critical patent/JP2014516088A5/ja
Application granted granted Critical
Publication of JP6347468B2 publication Critical patent/JP6347468B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014514934A 2011-06-10 2012-06-11 組換えフォンウィルブランド因子の投与による凝固疾患の治療 Active JP6347468B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US61/495,884 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US61/511,901 2011-07-26
US201161523790P 2011-08-15 2011-08-15
US61/523,790 2011-08-15
PCT/US2012/041957 WO2012171031A1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016137381A Division JP6527114B2 (ja) 2011-06-10 2016-07-12 組換えフォンウィルブランド因子の投与による凝固疾患の治療

Publications (3)

Publication Number Publication Date
JP2014516088A JP2014516088A (ja) 2014-07-07
JP2014516088A5 true JP2014516088A5 (enExample) 2015-07-30
JP6347468B2 JP6347468B2 (ja) 2018-06-27

Family

ID=46321496

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014514934A Active JP6347468B2 (ja) 2011-06-10 2012-06-11 組換えフォンウィルブランド因子の投与による凝固疾患の治療
JP2016137381A Active JP6527114B2 (ja) 2011-06-10 2016-07-12 組換えフォンウィルブランド因子の投与による凝固疾患の治療
JP2018246475A Pending JP2019048892A (ja) 2011-06-10 2018-12-28 組換えフォンウィルブランド因子の投与による凝固疾患の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016137381A Active JP6527114B2 (ja) 2011-06-10 2016-07-12 組換えフォンウィルブランド因子の投与による凝固疾患の治療
JP2018246475A Pending JP2019048892A (ja) 2011-06-10 2018-12-28 組換えフォンウィルブランド因子の投与による凝固疾患の治療

Country Status (24)

Country Link
US (2) US9272021B2 (enExample)
EP (3) EP3858375B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR20190041032A (enExample)
CN (3) CN108210889A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
BR (1) BR112013031795A2 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3412305T3 (enExample)
ES (3) ES2860450T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL3858375T3 (enExample)
PT (3) PT2717905T (enExample)
RU (2) RU2680402C2 (enExample)
SG (2) SG10201604684WA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108210889A (zh) * 2011-06-10 2018-06-29 百深有限责任公司 通过施用重组vwf治疗凝血疾病
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
SG11201808475XA (en) 2016-04-15 2018-10-30 Baxalta Inc Method and apparatus for providing a pharmacokinetic drug dosing regiment
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
AU2018298232B2 (en) * 2017-07-07 2025-04-03 Takeda Pharmaceutical Company Limited Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant VWF
US10632176B2 (en) 2017-07-07 2020-04-28 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
MY204220A (en) 2018-02-06 2024-08-16 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
MX2020009788A (es) * 2018-03-21 2020-12-09 Takeda Pharmaceuticals Co Separación de factor de von willebrand (vwf) y propéptido de factor de von willebrand (vwf) por métodos cromatográficos.
KR20210134642A (ko) * 2019-02-01 2021-11-10 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf (rvwf)를 이용한 예방 치료 방법
US20220401524A1 (en) * 2019-09-11 2022-12-22 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
AR121268A1 (es) 2020-02-04 2022-05-04 Takeda Pharmaceuticals Co Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
IL303089A (en) * 2020-11-24 2023-07-01 Band Therapeutics Llc Compositions and methods for treatment of bleeding disorders
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
KR20070092754A (ko) * 2004-12-27 2007-09-13 백스터 인터내셔널 인코포레이티드 중합체 - 폰 빌레브란트 인자 - 접합체
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのvwf安定化fviii製剤及びfviiiなしのvwf製剤の使用
BRPI0820271A2 (pt) 2007-11-09 2015-05-26 Baxter Int Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada.
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
NZ586383A (en) * 2007-12-28 2012-11-30 Baxter Int Recombinant vwf formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
TWI670072B (zh) * 2008-10-21 2019-09-01 美商巴克斯歐塔公司 凍乾的重組vwf調配物
JP2013500743A (ja) * 2009-08-04 2013-01-10 バクスター・インターナショナル・インコーポレイテッド Fviiiおよびvwfがノックアウトされた遺伝子導入マウス−血友病aモデル
ES3037386T3 (en) 2010-07-08 2025-10-01 Takeda Pharmaceuticals Co Method of producing recombinant high molecular weight vwf in cell culture
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
CN108210889A (zh) * 2011-06-10 2018-06-29 百深有限责任公司 通过施用重组vwf治疗凝血疾病

Similar Documents

Publication Publication Date Title
JP2014516088A5 (enExample)
RU2017102679A (ru) Лечение нарушений свертываемости крови путем введения рекомбинантного фв
CN103917554B (zh) 用于改善重构后纯化的因子viii的稳定性的方法
Lethagen et al. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III
JP2016514132A5 (enExample)
Federici et al. Clinical efficacy of highly purified, doubly virus‐inactivated factor VIII/von Willebrand factor concentrate (Fanhdi®) in the treatment of von Willebrand disease: a retrospective clinical study
JP2016516722A5 (enExample)
JP2014530873A5 (enExample)
NZ701205A (en) Optimised subcutaneous therapeutic agents
EP4255566A1 (en) Treatment of hemophilia with fitusiran
MX2009013183A (es) Uso de la proteina de fusion taci-ig, tal como atacicept, para la elaboracion de un medicamento para tratar lupus eritematoso.
EP4424366A3 (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
JP2014530246A5 (enExample)
KR20140083036A (ko) 인자 viii의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
TW202021611A (zh) 用於治療再生不良性貧血之醫藥組合物
McDaniel Treatment of Hemophilia A and B
AR118608A2 (es) TRATAMIENTO DE LOS TRASTORNOS DE LA COAGULACIÓN MEDIANTE LA ADMINISTRACIÓN DE UN FACTOR DE VON WILLEBRAND (vWF) RECOMBINANTE
AU2019202876B2 (en) Administration of Recombinant Collagen 7 for the Treatment of Age Related Disorders
JP2019524089A5 (enExample)
Nogami et al. Pathogenesis and treatment of hemophilia
EP1635861A1 (en) Compositions comprising factor viii and factor ixa for treating haemophilia
MX2024001882A (es) Metodo para producir factor viii / factor de von willebrand derivado de plasma humano y composicion obtenida.
Huth-Kühne Cautions and caveats to the treatment of acquired hemophilia A
Franchini Onset of severe refractory thrombocytopenia following surgery in a patient with type 2B von Willebrand disease—A case report
Lissitchkov et al. Recombinant Factor VIII Combined With Recombinant Von Willebrand Factor In Patients With Severe Hemophilia A: A Prospective Clinical Study Of Safety and Pharmacokinetics